Becton Dickinson and Co (BDX) Director Sells $58,737,559.02 in Stock

Becton Dickinson and Co (NYSE:BDX) Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the sale, the director now directly owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Becton Dickinson and Co (BDX) traded up $2.14 during mid-day trading on Monday, hitting $219.28. 1,078,442 shares of the company’s stock were exchanged, compared to its average volume of 1,647,500. Becton Dickinson and Co has a 12-month low of $175.66 and a 12-month high of $248.39. The stock has a market capitalization of $50,170.00, a PE ratio of 166.87, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the company earned $2.33 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. research analysts expect that Becton Dickinson and Co will post 10.95 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is 229.01%.

Hedge funds have recently added to or reduced their stakes in the business. Legacy Advisors LLC increased its position in shares of Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 490 shares during the period. FTB Advisors Inc. increased its position in shares of Becton Dickinson and by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 290 shares during the period. Penserra Capital Management LLC purchased a new position in shares of Becton Dickinson and in the fourth quarter valued at about $136,000. Harfst & Associates Inc. increased its position in shares of Becton Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares during the period. Finally, Exane Derivatives increased its position in shares of Becton Dickinson and by 848.6% in the fourth quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 628 shares during the period. Hedge funds and other institutional investors own 75.56% of the company’s stock.

A number of research firms have recently issued reports on BDX. Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a research report on Tuesday, October 31st. Bank of America reiterated a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research report on Friday, January 19th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $260.00 target price (up previously from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Finally, Evercore ISI assumed coverage on shares of Becton Dickinson and in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $237.27.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/becton-dickinson-and-co-bdx-director-sells-58737559-02-in-stock.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply